Table 4.
Modification of the association of Val16Ala with 10-year breast cancer survival by receipt of chemotherapy*
| Univariate | Multivariate$ | |||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | n | HR (95% CI) | P-value | n | |
| No Chemotherapy | (n=221) | (n=161) | ||||
| Val/Val | 1 (ref.) | 58 | 1 (ref.) | 42 | ||
| Val/Ala | 0.96 (0.49–1.87) | 0.898 | 111 | 1.28 (0.56–2.93) | 0.563 | 81 |
| Ala/Ala | 1.31 (0.62–2.75) | 0.480 | 52 | 1.47 (0.57–3.74) | 0.424 | 38 |
| Val/Ala & Ala/Ala | 1.06 (0.57–1.99) | 0.846 | 163 | 1.24 (0.58–2.64) | 0.569 | 119 |
| Ptrend | 0.488 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 169 | 1 (ref.) | 123 | ||
| Ala/Ala | 1.33 (0.73–2.43) | 0.345 | 52 | 1.60 (0.81–3.16) | 0.175 | 38 |
| Chemotherapy | (n=322) | (n=293) | ||||
| Val/Val | 1 (ref.) | 85 | 1 (ref.) | 77 | ||
| Val/Ala | 1.42 (0.90–2.25) | 0.130 | 166 | 1.24 (0.76–2.02) | 0.385 | 153 |
| Ala/Ala | 2.41 (1.47–3.94) | <0.001 | 71 | 2.47 (1.46–4.19) | 0.001 | 63 |
| Val/Ala & Ala/Ala | 1.68 (1.09–2.58) | 0.018 | 137 | 1.58 (1.01–2.49) | 0.047 | 216 |
| Ptrend | 0.001 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 251 | 1 (ref.) | 230 | ||
| Ala/Ala | 1.87 (1.29–2.71) | 0.001 | 71 | 1.95 (1.32–2.90) | 0.001 | 63 |
| Doxorubicin containing therapy | (n=160) | (n=149) | ||||
| Val/Val | 1 (ref.) | 44 | 1 (ref.) | 41 | ||
| Val/Ala | 1.12 (0.60–2.10) | 0.709 | 84 | 0.90 (0.47–1.75) | 0.775 | 79 |
| Ala/Ala | 2.76 (1.41–5.40) | 0.003 | 32 | 2.90 (1.33–6.32) | 0.007 | 29 |
| Val/Ala & Ala/Ala | 1.50 (0.84–2.67) | 0.169 | 116 | 1.21 (0.67–2.22) | 0.523 | 108 |
| Ptrend | 0.003 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 128 | 1 (ref.) | 120 | ||
| Ala/Ala | 2.57 (1.53–4.35) | <0.001 | 32 | 2.64 (1.48–4.69) | 0.001 | 29 |
| 5-Fluorouracil containing therapy | (n=121) | (n=112) | ||||
| Val/Val | 1 (ref.) | 25 | 1 (ref.) | 24 | ||
| Val/Ala | 2.95 (1.03–8.50) | 0.045 | 64 | 2.87 (0.94–8.74) | 0.064 | 59 |
| Ala/Ala | 4.63 (1.56–13.7) | 0.006 | 32 | 5.99 (1.71–21.0) | 0.005 | 29 |
| Val/Ala & Ala/Ala | 3.49 (1.25–9.74) | 0.017 | 96 | 4.12 (1.40–12.1) | 0.010 | 88 |
| Ptrend | 0.004 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 89 | 1 (ref.) | 83 | ||
| Ala/Ala | 1.90 (1.05–3.42) | 0.033 | 32 | 2.07 (1.10–3.88) | 0.023 | 29 |
| Cyclophosphamide containing therapy | (n=142) | (n=123) | ||||
| Val/Val | 1 (ref.) | 35 | 1 (ref.) | 31 | ||
| Val/Ala | 2.72 (1.03–7.14) | 0.042 | 74 | 1.92 (0.69–5.29) | 0.208 | 64 |
| Ala/Ala | 5.82 (2.17–15.51) | <0.001 | 33 | 22.0 (5.22–92.9) | <0.001 | 28 |
| Val/Ala & Ala/Ala | 3.56 (1.41–8.98) | 0.007 | 107 | 3.22 (124–8.38) | 0.016 | 92 |
| Ptrend | <0.001 | |||||
| Val/Val & Val/Ala | 1 (ref.) | 109 | 1 (ref.) | 95 | ||
| Ala/Ala | 2.86 (1.62–5.06) | <0.001 | 33 | 4.60 (2.29–9.21) | <0.001 | 28 |
*
Analysis included 543 patients. Information on receipt of chemotherapy was not available for 12 Norwegian patients and 18 US patients.
$
Cox Proportional-Hazards regression with adjustments for age at diagnosis, study site, race, tumor size, tumor grade, nodal involvement, p53 mutation and estrogen receptor status.